Media coverage about Biocept (NASDAQ:BIOC) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biocept earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.3659776970223 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Biocept (NASDAQ:BIOC) opened at $0.29 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.41 and a quick ratio of 1.27. The company has a market cap of $8.85, a price-to-earnings ratio of -0.33 and a beta of 1.98. Biocept has a 52-week low of $0.29 and a 52-week high of $2.76.

Biocept (NASDAQ:BIOC) last posted its earnings results on Thursday, November 9th. The medical research company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $1.39 million. Biocept had a negative net margin of 375.28% and a negative return on equity of 359.21%. research analysts predict that Biocept will post -0.76 earnings per share for the current fiscal year.

A number of research analysts recently commented on BIOC shares. Zacks Investment Research raised shares of Biocept from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. ValuEngine raised shares of Biocept from a “strong sell” rating to a “sell” rating in a research report on Monday, October 16th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $1.50 target price (down from $2.50) on shares of Biocept in a research report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Biocept presently has a consensus rating of “Hold” and an average price target of $1.75.

WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Insider Buying and Selling by Quarter for Biocept (NASDAQ:BIOC)

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.